1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

In development [GID-TA11514] Expected publication date: TBC

  • Project information
  • Project documents

NICE is considering whether new evidence has emerged that would affect the recommendation of TA762.


  • Review proposal paper MSWord 48 KB 08 April 2024  
  • Stakeholder matrix MSWord 64 KB 08 April 2024